1.82  0.09 (5.2%)		11-11 16:00
Open: 1.69 High: 1.82 Volume: 21,577		Pre. Close: 1.73 Low: 1.69 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	2.86	1-year :	3.44
Resists	First :	2.45	Second :	2.95
Pivot price	2.05
Supports	First :	1.64	Second :	1.37
MAs	MA(5) :	1.73	MA(20) :	2.16
	MA(100) :	2.29	MA(250) :	2.18
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	7.9	D(3) :	5.5
RSI	RSI(14): 35.2
52-week	High :	4.48	Low :	1.54

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EDSA ] has closed above bottom band by 35.6%. Bollinger Bands are 251.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 26 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.82 - 1.83	1.83 - 1.83
Low:	1.67 - 1.68	1.68 - 1.69
Close:	1.81 - 1.82	1.82 - 1.83

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Fri, 07 Nov 2025
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade

Mon, 03 Nov 2025
HC Wainwright & Co. Reiterates Edesa Biotech (EDSA) Buy Recommendation - Nasdaq

Mon, 03 Nov 2025
Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus

Fri, 31 Oct 2025
Edesa Biotech Announces Upcoming Conference Schedule - Sahm

Fri, 31 Oct 2025
Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st

Fri, 31 Oct 2025
Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	4 (M)
Held by Insiders	28.7 (%)
Held by Institutions	29.9 (%)
Shares Short	9 (K)
Shares Short P.Month	7 (K)

EPS	-1.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.69
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-40.3 %
Return on Equity (ttm)	-69.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.87
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-1.47
PEG Ratio	0
Price to Book value	2.6
Price to Sales	0
Price to Cash Flow	-2.04

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.